Patient Characteristics Are Compared with Outcome
| MBq infused | Age (y) | No. of chemotherapy regimens* | Ascites | Largest tumor (cm) (includes nodes) | No. of masses > 1 cm | HER-2 immunohistochemistry score | ELISA | Response 6 wk | Mo. since treatment |
| 15 | 46 | 5 | Limited | 3.4 | 5 | 2+; >30% | 10.3 | S | 9† |
| 11 | 67 | 5 | Limited | 2.8 | 5 | 1+; >30% | NA | S | 24 |
| 11 | 83 | 3 | Large | 4 | 2 | 2+; >30% | 9.6 | P | 14† |
| 13 | 60 | 3 | 0 | 1.8 | 5 | 1+; >30% | 12.3 | S | 18 |
| 17 | 62 | 1 | 0 | 2.5 | 3 | 2+; >30% | 13.7 | P | 2† |
| 21 | 77 | 2 | Large | 2.9 | 1 | 1+; <10% | 14.6 | P | 2† |
| 21 | 66 | 9 | 0 | 2.6 | 4 | 1+; >30% | 12.3 | S | 11† |
| 19 | 59 | 4 | 0 | 4.3 | 3 | 1+; >30% | 14.7 | S | 14 |
| 25 | 80 | 2 | 0 | 7.2 | 5 | 1+; >10% | 13.7 | S | 4† |
| 19 | 71 | 3 | 0 | ne | 0 | 1+; >30% | 12.2 | S | 11 |
| 31 | 54 | 8 | 0 | 3.9 | 4 | 1+; >30% | NA | S | 9 |
| 28 | 68 | 5 | 0 | 4.5 | 2 | NA | 16.4 | P | 9 |
| 31 | 72 | 2 | Large | 5.1 | 5 | 1+; >30% | 18.9 | S | 8 |
| 39 | 59 | 4 | Limited | 1.2 | 3 | 1+; >30% | 15.2 | S | 5 |
| 40 | 73 | 2 | 0 | 1.5 | 1 | 2+; >10% | NA | S | 4 |
| 38 | 61 | 1 | 0 | 1.3 | 2 | 1+; >30% | 9.2 | S | 4 |
↵* Number of chemotherapy cycles ranged from 6 to 64. Most common regimens contained taxane or platinum, followed by anthracycline, gemcitabine, and topotecan as cytotoxic chemotherapy. Intraperitoneal chemotherapy was a component in a few regimens. Some regimens included bevacizumab, other antibody, vaccine, molecularly targeted inhibitor, or adenoviral vector therapy. Hormonal agents were not considered as regimens.
↵† Deaths.
S = stable; P = disease progression NA = not applicable.